|7.96||-0.2400||-2.93%||Vol 1.57M||1Y Perf 114.17%|
|Apr 19th, 2021 16:00 DELAYED|
|- -||-0.04 -0.50%|
|Target Price||15.75||Analyst Rating||Strong Buy 1.00|
|Potential %||97.86||Finscreener Ranking||★★★★ 54.06|
|Insiders Trans % 3/6/12 mo.||-100/-50/-20||Value Ranking||★+ 45.27|
|Insiders Value % 3/6/12 mo.||-100/-95/-94||Growth Ranking||★★+ 50.83|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-90/-88||Income Ranking||— -|
|Market Cap||531.39M||Earnings Rating||Strong Buy|
|Price Range Ratio 52W %||20.87||Earnings Date||10th May 2021|
Today's Price Range
5 Year PE Ratio Range
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||10th May 2021|
|Estimated EPS Next Report||-0.09|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||737.23K|
|Avg. Monthly Volume||1.12M|
|Avg. Quarterly Volume||3.83M|
ChromaDex Corporation (NASDAQ: CDXC) stock closed at 7.96 per share at the end of the most recent trading day (a -2.93% change compared to the prior day closing price) with a volume of 1.57M shares and market capitalization of 531.39M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 110 people. ChromaDex Corporation CEO is Robert N. Fried.
The one-year performance of ChromaDex Corporation stock is 114.17%, while year-to-date (YTD) performance is 65.83%. CDXC stock has a five-year performance of 83.83%. Its 52-week range is between 3.82 and 23.66, which gives CDXC stock a 52-week price range ratio of 20.87%
ChromaDex Corporation currently has a PE ratio of -24.80, a price-to-book (PB) ratio of 33.33, a price-to-sale (PS) ratio of 11.83, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -48.49%, a ROC of -89.90% and a ROE of -103.02%. The company’s profit margin is -30.87%, its EBITDA margin is -31.00%, and its revenue ttm is $44.91 Million , which makes it $0.67 revenue per share.
Of the last four earnings reports from ChromaDex Corporation, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.09 for the next earnings report. ChromaDex Corporation’s next earnings report date is 10th May 2021.
The consensus rating of Wall Street analysts for ChromaDex Corporation is Strong Buy (1), with a target price of $15.75, which is +97.86% compared to the current price. The earnings rating for ChromaDex Corporation stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
ChromaDex Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
ChromaDex Corporation has a Neutral technical analysis rating based on Technical Indicators (ADX : 46.67, ATR14 : 1.56, CCI20 : -145.57, Chaikin Money Flow : -0.41, MACD : 0.31, Money Flow Index : 48.91, ROC : -14.78, RSI : 51.24, STOCH (14,3) : 0.61, STOCH RSI : 0.00, UO : 27.48, Williams %R : -99.39), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of ChromaDex Corporation in the last 12-months were: Frank L. Jaksch (Option Excercise at a value of $192 502), Frank L. Jaksch (Sold 37 829 shares of value $196 333 ), Kevin M. Farr (Buy at a value of $22 150), Robert N. Fried (Buy at a value of $4 690), Stephen A. Block (Option Excercise at a value of $114 500), Stephen A. Block (Sold 52 500 shares of value $625 775 )
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.